标题：肝硬化顽固性腹水的治疗进展

      作者：成美娇，郑伟强    广东医科大学附属医院感染内科，广东 湛江 524000

      卷次： 2019年30卷2期

      【摘要】 肝硬化失代偿期因严重的钠水潴留可逐渐发展为顽固性腹水。顽固性腹水发生机制仍未完全阐明，并且对限钠、利尿、护肝、补充白蛋白、放腹水等传统治疗措施效果欠佳，死亡率高。本文就顽固性腹水发生机制及治疗方法给予综述。
      【关键词】 顽固性腹水；特利加压素；托伐普坦；自动低流量腹水泵；腹水超滤浓缩回输术
      【中图分类号】 R575.2 【文献标识码】 A 【文章编号】 1003—6350（2019）02—252—04<
span style='font-style:italic'>P
rogress on the treatment of patients with cirrhosis and refractory ascites.
CHENG Mei-jiao, ZHENG Wei-qiang.Department of Infectious Disease, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, Guangdong,CHINA【Abstract】 The patients with liver cirrhosis can develop refractory ascites gradually due to severe sodium andwater retention. The mechanism of refractory ascites is still not fully elucidated, and the traditional treatment measuressuch as sodium restriction, diuresis, liver protection, albumin supplementation and ascites are not effective and the mor-tality rate is high. This article reviews the mechanism and treatment of refractory ascites.
      【Key words】 Refractory ascites; Terlipressin; Tolvaptan; Automatic low flow ventral pump; Ascites reinfusion ul-trafiltration therapy·综述·doi:10.3969/j.issn.1003-6350.2019.02.033基金项目：广东省医学科研基金(编号：A2017455)；广东省湛江市财政科技专项竞争性分配项目(编号：2017A01018)